Articles from Diality Inc.

Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027.

Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas.

Diality Inc., a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.

Diality Inc. today announced that it will introduce its Moda-flx Hemodialysis System™ at ASN Kidney Week 2023, Nov. 1-5 at the Pennsylvania Convention Center in Philadelphia. The technology will also be the subject of a poster session titled “Blood Flowrate Accuracy with Diality Hemodialysis System” [SA-P0618] to be presented from 10 a.m. to noon on Saturday, Nov. 4 in the exhibit hall.

Diality Inc., a medical technology company developing a user friendly, mobile and connected hemodialysis system with a category leading prescription range, today announced the closing of a $28 million investment round. The funding will be used to support Diality’s 510(k) filing and pre-commercialization activities through initial commercial launch targeting hospitals, skilled nursing facilities, and de novo clinics. The funding will also support initiation and early enrollment of Diality’s U.S. home hemodialysis clinical trial.

Diality Inc., a medical technology company developing a smart, mobile hemodialysis platform, today announced the hiring of Pamela Wapnick as chief financial officer. She brings to the company more than 30 years of highly diversified financial experience, primarily in the biotech and pharmaceutical industries, as it readies for the commercial launch of its technology in 2023.